Editorial
Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodies
First published: 26 March 2001
No abstract is available for this article.
REFERENCES
- 1
Charles PJ,
Smeenk RJT,
DeJong J,
Feldmann M,
Maini RN.
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials.
Arthritis Rheum
2000;
43:
2383–2390.
- 2
Elliot MJ,
Maini RN,
Feldmann M,
Long-Fox A,
Charles P,
Katsikis P, et al.
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α.
Arthritis Rheum
1993;
36:
1681–90.
- 3
Moreland LW,
Baumgartner SW,
Schiff MH,
Tindall EA,
Fleischmann RM,
Weaver AL, et al.
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
N Engl J Med
1997;
337:
141–7.
- 4
Jacob CO,
McDevitt HO.
Tumor necrosis factor-α in murine autoimmune ‘lupus’ nephritis.
Nature
1988;
331:
356–8.
- 5
Jacob CO.
Tumor necrosis factor α in autoimmunity: pretty girl or old witch?
Immunol Today
1992;
13:
122–5.
- 6
Gordon C,
Ranges GE,
Greenspan JS,
Wofsy D.
Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice.
Clin Immunol Immunopathol
1989;
52:
421–4.
- 7
Foster MH,
Cizman B,
Madaio MP.
Biology of disease: nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins.
Lab Invest
1993;
69:
494–507.
- 8
Lefkowith JB,
Gilkeson GS.
Nephritogenic autoantibodies in lupus: current concepts and continuing controversies.
Arthritis Rheum
1996;
39:
894–903.
- 9
Pisetsky DS.
Antibody responses to DNA in normal immunity and aberrant immunity.
Clin Diag Lab Immunol
1998;
5:
1–6.
